Deanne Rendock, APRN
Adult Health · Bridgeport, CTNPI 1831294321
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 767 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by GSK at 32.5% of the total. 2025 is the largest year on record at $3,946, 2.5 times the $1,600 reported in 2021. Among adult health clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 767 payments — averaging $18.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$5K
- AstraZeneca$3K
- Regeneron Healthcare Solutions, Inc.$1K
- Boehringer Ingelheim$617
- Mylan Specialty L.p.$569
- Amgen$524
- plus $4K from 26 others
What the payments were for
- Food & beverage$14,224100%
- Education$550%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 293 | $4,641 |
| AstraZeneca | 122 | $3,091 |
| Regeneron Healthcare Solutions, Inc. | 50 | $1,080 |
| Boehringer Ingelheim | 31 | $617 |
| Mylan Specialty L.p. | 43 | $569 |
| Amgen | 32 | $524 |
| Sanofi | 27 | $521 |
| Insmed, Inc. | 27 | $456 |
| Harmony Biosciences LLC | 16 | $440 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $299 |
| Verona Pharma, Inc. | 14 | $270 |
| Actelion Pharmaceuticals US, Inc. | 15 | $267 |
| Viatris Specialty LLC | 14 | $219 |
| Baxter Healthcare | 12 | $219 |
| Philips North America LLC | 9 | $161 |
| Genentech USA, Inc. | 8 | $149 |
| Covis Pharma GmbH | 6 | $114 |
| Electromed, Inc. | 6 | $89 |
| Mallinckrodt Hospital Products Inc. | 4 | $77 |
| Inogen, Inc. | 4 | $76 |
| Johnson & Johnson | 4 | $65 |
| Lilly USA, LLC | 2 | $50 |
| Novartis | 2 | $49 |
| Sunovion Pharmaceuticals Inc. | 3 | $44 |
| Azurity Pharmaceuticals, Inc. | 2 | $41 |
| Jazz Pharmaceuticals Inc. | 2 | $38 |
| AbbVie | 1 | $27 |
| Advanced Respiratory, Inc | 1 | $22 |
| Phadia US Inc. | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| 3b Medical, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,279 in reported general payments places this provider in the 95th percentile of 418 adult health providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 29 | $342,645 |
| XolairOmalizumab | 73 | $240,622 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 250 | $211,878 |
| Fasenra PenBenralizumab | 13 | $73,350 |
| Dupixent SyringeDupilumab | 12 | $52,955 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 47 | $35,836 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 56 | $35,469 |
| Breo ElliptaFluticasone/Vilanterol | 54 | $30,795 |
| Spiriva RespimatTiotropium Bromide | 26 | $14,420 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 27 | $9,031 |
| JardianceEmpagliflozin | 12 | $7,140 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $5,943 |
| Qvar RedihalerBeclomethasone Dipropionate | 11 | $5,416 |
| Advair DiskusFluticasone Propion/Salmeterol | 15 | $5,090 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 265 | $4,858 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Jardiance | $617 | $364,20567 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $4,641 | $284,451362 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $3,091 | $39,16968 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 418 adult health providers in Connecticut.
Other adult health in Bridgeport
- Shirley KuanBridgeport$6K
- Wendy AwaBridgeport$5K
- Leah EhleManchester$418K
- Laura MulkaWethersfield$306K
- Gretchen MichaelsonSouth Windsor$169K
- Kimberly RyanWethersfield$74K
- Kathryn JackMeriden$67K
- Lynn RapsilberTorrington$52K
- Genice NelsonFarmington$36K
- Andrea LauterNew London$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.